Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Source filing unavailable
Q2 2014 · —
Revenue$110.33M$110.33M+33.8% vs Q2 2013 Net Income$5.03M$5.03M−52.0% vs Q2 2013 EPS Diluted$0.13$0.13−55.2% vs Q2 2013 Operating Income$7,862,000−46.6% Operating Cash Flowderived$10,819,000−67.0% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Free Cash Flowderived
Margins · derivedOperating margin7.1%−10.7 pt vs Q2 2013
Net margin4.6%−8.2 pt vs Q2 2013